Administrative and Statistical Core Resource

核心A摘要/摘要 我们建议的U54中心申请，题为最佳免疫治疗的发现和发展 儿童癌症战略是一项多学科和多机构的努力，我们认为直接 响应旨在创建儿科免疫疗法发现和开发网络的RFA (PI-DDN)。建立在项目和核心主要研究人员之间多年的多学科合作基础上 和他们的研究团队，我们计划直接解决与儿童独特相关的关键未得到满足的需求 高危癌症。为了实现我们的中心目标，我们建议经验丰富的领导来确定优先事项， 保持势头，按时并在预算范围内完成预定的里程碑。建议数 Maris博士和Mackall博士曾共同领导复杂的研究项目并协调 一体化、协作式实验。在这里，我们建议一个管理核心，它将提供 科学、统计和行政领导，以实现拟议调查的使命。使用 经验丰富的统计和行政支持，我们将组织定期会议和日常工作 该中心的运作以及与PI-DDN和其他免疫治疗努力的互动。核心意志 支持每个项目和中心实现雄心勃勃的科学目标所需的科学交流 总的来说，鼓励儿科癌症倡导者的投入，以帮助塑造我们的使命，监督分配 根据我们的研究进展按季度编制预算，确保合规性，并促进试验性 严谨和透明。

CORE A SUMMARY/ABSTRACT Our proposed U54 Center application entitled Discovery and Development of Optimal Immunotherapeutic Strategies for Childhood Cancers is a multi-disciplinary and multi-institutional effort that we think is directly responsive to the RFAs designed to create the Pediatric Immunotherapy Discovery and Development Network (PI-DDN). Built on years of multi-disciplinary collaboration amongst Project and Core Principal Investigators and their research teams, we plan to directly address critical unmet needs uniquely relevant to children with high-risk cancers. To accomplish our Center goals, we propose experienced leadership to define priorities, sustain momentum and deliver results that meet defined milestones on time and under budget. The proposed co-PIs Drs. Maris and Mackall have worked together to lead complex research programs and coordinate integrated and collaborative experimentation. Here, we propose an administrative Core that will provide the scientific, statistical and administrative leadership to achieve the mission of the proposed investigation. With experienced statistical and administrative support, we will organize the recurring meetings and day-to-day operation of the Center and interactions with the PI-DDN and other immunotherapy efforts. The Core will support the scientific interchange necessary for the ambitious scientific goals of each Project and the Center as a whole, encourage input from pediatric cancer advocates to help shape our mission, oversee the allocation of budget on a quarterly basis as our research evolves, assure regulatory compliance, and promote experimental rigor and transparency.